Biopharmaceutical companies face a broad range of challenges when developing new large-molecule products, including Potential failures in the clinic or, even worse, an inability to manufacture because of an increase in the number of complex molecules in a company’s pipeline Under- or over-manufacture of a drug substance raw material because of demand uncertainty Limited access to right-sized capacity, driven by the bioprocess industry’s shift away from large-volume stainless steel tanks toward mid-scale bioreactors A company’s inability to find a manufacturing…